Results 91 to 100 of about 2,225,697 (249)

Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective

open access: yesIndian Journal of Ophthalmology
Purpose: To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE). Methods: This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023.
Akshay Badakere   +5 more
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Acquired epidermodysplasia verruciformis secondary to methotrexate

open access: yesJAAD Case Reports, 2023
Mohammed A. AlFada, MD, MBA   +1 more
doaj   +1 more source

Carbon baby syndrome: A case report with review of literature

open access: yesIndian Journal of Paediatric Dermatology
Carbon baby syndrome also known as universal acquired melanosis is one of the rare causes of diffuse and progressive hyperpigmentation of the skin. A case of a 9-year-old Nepali child was reported in whom darkening of the skin began at the age of 5 ...
Sandhya Kumari   +3 more
doaj   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

A congenital fibular notch synostosis of the left distal leg: a case report [PDF]

open access: yesJournal of Research in Applied and Basic Medical Sciences
Background & Aims: Tibiofibular synostosis is an infrequent, limb malformation that is non-syndromic and illustrated by the union of the proximal or distal tibia and union of the proximal or distal tibial and fibular metaphysis and/ or diaphysis ...
Olubunmi Balogun   +6 more
doaj  

Home - About - Disclaimer - Privacy